Pediatric-like therapy for adults with ALL

Current Hematologic Malignancy Reports

Volumn 9, Issue 2, 2014, Pages 158-164

  Dombret, Hervé ^a   Cluzeau, Thomas ^a   Huguet, Françoise ^b   Boissel, Nicolas ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Acute lymphoblastic leukemia; Pediatric like therapy; Ph positive ALL; Stem cell transplantation

Indexed keywords

CYTARABINE; IMATINIB; METHOTREXATE; MITOXANTRONE; NILOTINIB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; OVERALL SURVIVAL; PEDIATRIC LIKE THERAPY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; RISK FACTOR; ADOLESCENT; ADULT; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK; SURVIVAL RATE; YOUNG ADULT;

EID: 84903575418     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0210-9     Document Type: Article

References (35)

1. Pui CH, Relling MV, Downing JR. N Engl J Med. 2004;350:1535-48.
2. Pui CH, Robison LL, Look AT. Lancet. 2008;371:1030-43.
3. Roberts KG, Payne-Turner D, Pei D, et al. Integrated genomic and mutational profiling of adolescent and young adult ALL identifies a high frequency of BCR-ABL1-like ALL with very poor outcome. Blood (ASH Annual Meeting Abstract) 2013;122:825.
4. .•• Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-80. First publication showing the impressive gain in outcome of adolescents and young adults with ALL when treated with a pediatric rather than an adult protocol. (Pubitemid 46606434)
5. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032-5. (Pubitemid 40028431)
6. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48:254-61. (Pubitemid 46238513)
7. Hallböök H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107:1551-61. (Pubitemid 44546916)
8. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group B studies. Blood. 2008;112:1646-54.
9. Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood (ASH Annual Meeting Abstracts) 2004;104:1954.
10. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760-1. (Pubitemid 46606430)
11. De Angelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2007;110:587.
12. Douer D, Watkins K, Mark L, et al. A dose intensified pediatric-like regimen using multiple doses of intravenous pegylated asparaginase in adults with newly diagnosed acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2007;110:2823.
13. Haïat S, Marjanovic Z, Lapusan S, et al. Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol. Leuk Res. 2011;35:66-72.
14. •• Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843-9. Prospective study showing that a pediatric protocol may be administered in young adults with ALL until 30 years of age.
15. .•• Rijneveld AW, van der Holt B, Daenen SM, et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25(11):1697-703. Another prospective study showing that a pediatric protocol may be administered in young adults with ALL until 40 years of age.
16. Cluzeau T, Dhedin N, Huguet, F, et al. Dose-intensity impacts on survival of adolescents and young adults with acute lymphoblastic leukemia treated in adult departments by a pediatric protocol (FRALLE 2000BT). Blood (ASH Annual Meeting Abstracts) 2012;120:3561.
17. Faderl S, Thomas DA, O'Brien S, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11:54-9.
18. Rytting ME, Thomas DA, O'Brien S, et al. Augmented Berlin-Frankfurt- Muenster based therapy for young adults with acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2013;122:1400.
19. Sakura T, Hayakawa F, Yujiri T, et al. Outcome of pediatric-type therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA): A study by the Japan Adult Leukemia Study Group (JALSG ALL202-U study). Blood (ASH Annual Meeting Abstracts) 2012;120:1464.
20. Radi S, Merdad A, Al-Dabbagh M, et al. Outcome and toxicities of modified augmented Berlin-Frankfurt-Muenster (ABFM) therapy used in the treatment of acute lymphoblastic leukemia in adolescent and young adult patients, single center experience from Saudi Arabia. Blood (ASH Annual Meeting Abstracts) 2012;120:3569.
21. Advani AS, Sanford B, Luger S, et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: Toxicity results of the prospective US Intergroup Trial C10403 (Alliance). Blood (ASH Annual Meeting Abstracts) 2013;122:3903.
22. Gökbuget N, Arnold R, Böhme A, et al. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. Blood (ASH Annual Meeting Abstracts) 2007;110:12.
23. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911-8.
24. Gökbuget N, Beck J, Brandt K, et al. Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL). Blood (ASH Annual Meeting Abstracts) 2013;122:839.
25. Bassan R, Intermesoli T, Oldani E. Prognostic factors and risk adapted therapy. In «Recommendations of the European Working Group for Adult ALL (EWALL)». 2011 (UNI-MED Verlag AG D-28323 Bremen).
26. Van der Veer A, Waanders E, Pieters P, et al. Independent prognostic value of BCR-ABL-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122:2622-9.
27. Ben Abdelali R, Asnafi V, Leguay T, et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favourable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood. 2011;118:5099-107.
28. •• Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Towards a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-ALL: a GRAALL study. J Clin Oncol. 2013;31: 4333-42. A powerful genetic-based risk model in adult ALL.
29. Beldjord K, Macintyre E, Lheritier V, et al. Minimal residual disease at 3 months, combined to the presence of IKZF1 deletion in B-Lineage or absence of NOTCH1 pathway mutation in T-Lineage, recapitulates the disease risk assessment in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia - A GRAALL study. Blood (ASH Annual Meeting Abstracts) 2011;118:572.
30. .•• Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868-76. To date, the largest study of minimal residual disease value in adult patients with ALL.
31. Dhedin N, Huynh A, Maury S, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): Results from the Group for Research on Adult ALL (GRAALL). Blood (ASH Annual Meeting Abstracts) 2013;122:552.
32. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-33. (Pubitemid 351451489)
33. Chalandon Y, Thomas X, Hayette S, et al. Is less chemotherapy detrimental in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) treated with high-dose imatinib? Results of the prospective randomized GRAAPH-2005 study. Blood (ASH Annual Meeting Abstracts) 2012;120:138.
34. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676-8. (Pubitemid 46641715)
35. Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521-8.